RayzeBio Future Growth
Future criteria checks 0/6
RayzeBio is forecast to grow earnings and revenue by 2% and 65.1% per annum respectively. EPS is expected to grow by 48.3% per annum. Return on equity is forecast to be -24.5% in 3 years.
Key information
2.0%
Earnings growth rate
48.3%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 65.1% |
| Future return on equity | -24.5% |
| Analyst coverage | Low |
| Last updated | 26 Feb 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -156 | -132 | -123 | 1 |
| 12/31/2025 | N/A | -137 | -98 | -89 | 1 |
| 12/31/2024 | N/A | -97 | -98 | -75 | 3 |
| 12/31/2023 | N/A | -75 | -126 | -71 | 3 |
| 9/30/2023 | N/A | -65 | -91 | -56 | N/A |
| 6/30/2023 | N/A | -70 | -75 | -51 | N/A |
| 3/31/2023 | N/A | -72 | -68 | -51 | N/A |
| 12/31/2022 | N/A | -73 | -61 | -52 | N/A |
| 12/31/2021 | N/A | -57 | -37 | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYZB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RYZB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RYZB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RYZB is forecast to have no revenue next year.
High Growth Revenue: RYZB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RYZB is forecast to be unprofitable in 3 years.